Targeted Therapeutic Against Bladder Cancer
Purdue University researchers have developed a novel strategy using an epidermal growth factor (EGF) targeted toxin, which can be used for elimination of both superficial and invasive bladder tumors. This is a highly efficient, targeted strategy that reduces treatment time from hours (current therapies) to minutes. Further, this agent can be administered by a pharmaceutically acceptable delivery system in the lumen of the bladder for treatment. In addition to being easily used against bladder cancer, this strategy is also applicable to other EGF receptor-dependent cancers such as lung and skin cancer.
High efficacy and fast action Targets superficial and invasive bladder tumors EGF targeting and internalization of the toxin
Treatment of bladder cancer Treatment of lung and skin cancer
Ruben AguilarPurdue Biological Sciences
United States
None
USA
